Your small intestine produces the hormone GLP-1
10.1002/dmrr.2713 Diabetes Metab Res Rev
Phase 2 trial (NEJM, 2023) The landmark Phase 2 trial, published in the New England Journal of Medicine, randomized 338 adults with obesity to receive weekly subcutaneous retatrutide at doses of 1 mg, 4 mg, 8 mg, or 12 mg, or placebo, for 48 weeks
75% of GLP-1 users believe they'll still be on their treatment plan a year from now
and 11,197,880 These statements have not been evaluated by the Food and Drug Administration
More research is needed before we can know whether GLP-1 agonists are truly safe during pregnancy